Price increases for generic medications: Sixty-Second Report of Session 2017–19: Report, together with formal minutes relating to the report – House of Commons Committee of Public Accounts

During 2017, the prices of certain generic medicines purchased by community pharmacies for the NHS increased unexpectedly, affecting an unusually high number of medicines. Although the Department of Health & Social Care (the Department) and its arms-length bodies took action

Surveillance of antimicrobial resistance in Neisseria gonorrhoeae in England and Wales: Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP): Data to May 2018 – Public Health England

Data on trends in antimicrobial resistance and decreased susceptibility in gonococcal infection in England and Wales provided by GRASP. Public Health England reports annually on drug resistance and decreased susceptibility in gonorrhoea in England and Wales and has twice provided data

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) – NHS England

Updated policy document outlines the arrangements for funding of the use of cobicistat as a booster in treatment of HIV infection (all ages).

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628] – NICE

Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder. This guidance replaces NICE interventional procedures guidance on intravesical microwave

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Pharmaceutical waste reduction in the NHS – NHS England

This report seeks to highlight best practice in relation to reducing pharmaceutical waste from local initiatives with the purpose of encouraging others to introduce similar initiatives where appropriate.

Pharmacological management of migraine: (SIGN 155) – Scottish Intercollegiate Guidelines Network

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache. This guideline will be of interest to healthcare professionals in primary and secondary care,

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: Technology appraisal guidance [TA540]

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours: Technology appraisal guidance [TA539] – NICE

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive

Rezum for treating benign prostatic hyperplasia: Medtech innovation briefing [MIB158] – NICE

The technology described in this briefing is Rezum, which uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benign prostatic hyperplasia. The innovative aspects are that the company claims that it is quicker to do than

Integrating NHS pharmacy and medicines optimisation into Sustainability and Transformation Partnerships and Integrated Care Systems – NHS England

This document describes the approach for “testing” the principles of a framework for NHS pharmacy and medicines integration within Sustainability and Transformation Partnership (STP) and Integrated Care System (ICS) pilot areas during 2018/19.

Drug Safety Update: Latest advice for medicines users: August 12 Issue 1 – Medicines and Healthcare products Regulatory Agency

Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.  Contains details of: Esmya (ulipristal acetate) and risk of serious liver injury: new restrictions to use and requirements for liver function monitoring before, during, and after treatment

Dinutuximab beta for treating neuroblastoma: Technology appraisal guidance [TA538] – NICE

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over. Recommendations Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least

Sustainability & Transformation Partnerships – Royal Pharmaceutical Society

Letter from the Royal Pharmaceutical Society to Sustainability & Transformation Partnerships Leads identifying the value and role of pharmacists as a workforce and the value of medicine optimisation in care homes.  It has been demonstrated that pharmacists undertaking a medicines review

Pharmaceutical buying groups in the NHS – Department of Health and Social Care

Provides details of purchasing point information for existing buying groups that have access to Commerical Medicines Unit (CMU) contracts. It can be filtered in various ways to produce individual purchasing point lists for each buying group currently in England. This could

An evaluation of the cost effectiveness of monitored dosage systems (MDS) as an aid to maintaining independence in taking medication: (LPHO Report Series, number 98, Rapid Evidence Review Series, number 2) – University of Liverpool Public Health Observatory

A monitored dosage system (MDS), usually in the form of a box or a blister pack divided into days of the week, is a medication storage device designed to simplify the administration of solid oral dose medication. MDS can potentially

Dupilumab for treating moderate to severe atopic dermatitis: Technology appraisal guidance [TA534] – NICE

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults. Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 other

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA537] – NICE

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults. Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as described in NICE’s technology appraisal

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine: Technology appraisal guidance [TA535] – NICE

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid